For an antiviral researcher, Covid brings a flood of attention — and opportunity

In February 2020, Jeffrey Glenn was prepping for a meeting at the Food and Drug Administration when his phone suddenly rang.

“What do you think about this virus?” asked the caller, a philanthropist who was worried about the pathogen that would later be named SARS-CoV-2.

Read the rest…